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Abstract
Advanced glycation endproducts (AGEs)-induced 
vascular smooth muscle cell (VSMCs) proliferation 
and formation of reactive oxygen species (ROS) are 
emerging as one of the important mechanisms of dia-
betic vasculopathy but little is known about the anti-
oxidative action of HMG CoA reductase inhibitor 
(statin) on AGEs. We hypothesized that statin might re-
duce AGEs-induced intracellular ROS of VSMCs and 
analyzed the possible mechanism of action of statin in 
AGEs-induced cellular signaling. Aortic smooth mus-
cle cell of Sprague-Dawley rat (RASMC) culture was 
done using the different levels of AGEs stimulation in 
the presence or absence of statin. The proliferation of 
RASMC, ROS formation and cellular signaling was 
evaluated and neointimal formation after balloon in-
jury in diabetic rats was analyzed. Increasing concen-
tration of AGEs stimulation was associated with in-
creased RASMC proliferation and increased ROS for-
mation and they were decreased with statin in a 
dose-dependent manner. Increased NF-κB p65, phos-
phorylated ERK, phosphorylated p38 MAPK, cyclo-
oxygenase-2, and c-jun by AGEs stimulation were not-
ed and their expression was inhibited by statin. 
Neointimal formation after balloon injury was much 
thicker in diabetic rats than the sham-treated group but 
less neointimal growth was observed in those treated 
with statin after balloon injury. Increased ROS for-
mation, subsequent activation of MAPK system and in-
creased VSMC proliferation may be possible mecha-
nisms of diabetic vasculopathy induced by AGEs and 
statin may play a key role in the treatment of AGEs-in-
duced diabetic atherosclerosis.
Keywords: cyclooxygenase 2; diabetes mellitus; ex-
tracellular signal-regulated MAP kinases; hydroxy-
methylglutaryl-CoA reductase inhibitors; muscle, 
smooth, vascular; NFκB; p38 mitogen-activated pro-
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Introduction
Recent studies have demonstrated that advanced 
glycation endproducts (AGEs) and their receptor- 
ligand interactions play a key role in neointimal 
formation after vascular injury, irrespective of dia-
betes status (Brownlee et al., 1988; Sakaguchi et 
al., 2003; Stephenson et al., 2003; Zhou et al., 
2003). AGEs stimulate the activation of the NFκB- 
dependent pathways and MAPK and subsequently 
induce proinflammatory mediators and increase 
oxidative stress (Bierhaus et al., 1997). 
    Reactive oxygen species (ROS) can function as 
signal transduction molecules and play an important 
role in the inflammatory process and atheroscle-
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Figure 1. Effect of AGEs and statin on proliferation of RASMCs. Proliferation was increased with AGEs treatment dose-dependently (A) and decreased 
with statin dose-dependently (AGE 50 μg/ml) (B). Cell proliferation was determined by MTT assay. Data are expressed as mean ± SEM (n = 5). *P ＜
0.05 versus control; †P ＜ 0.05 versus AGEs. CTL, control; AGEs, advanced glycation endproducts.
Figure 2. Effect of AGEs and statin on formation of intracellular ROS in RASMCs. Results shown are increased oxidative stress with AGEs treatment 
dose-dependently (A) and suppressive effect of statin on oxidative stress (AGE 50 μg/ml) (B). Data are expressed as mean ± SEM (n = 5). *P ＜ 0.05 
versus control; †P ＜ 0.05 versus AGEs. CTL, control; AGEs, advanced glycation endproducts.
rosis (Brown et al., 1999; Davignon, 2004). The 
antioxidative effect of statin has recently been 
noted as one of its pleiotrophic effects. Statin 
reduces intracellular ROS in endothelial cells by 
S-nitrosylation of thioredoxin (Haendeler et al., 
2004) as well as other various effects (Kim et al., 
2009). Recently, several reports have suggested 
that statin could act as an antioxidant in experi-
mental atherosclerosis in animals (Singh et al., 
1997; Takemoto et al., 2001; Wassmann et al., 
2002), inhibiting oxidation of LDL by activated 
monocyte-derived macrophages (Giroux et al., 
1993). Another recent article revealed that statin 
inhibited p38 MAPK and consequently inhibited 
membrane translocation of the small G protein 
family members (Ras1- and RhoA-) (Senokuchi et 
al., 2005). However despite the potent impact of 
statin on atherosclerosis, little is known about the 
molecular mechanism of statin as antioxidants. 
    Therefore, we hypothesized that statin might 
reduce AGEs-induced intracellular ROS generation 
and also analyzed the possible mechanism of 
action of statin in ROS-induced cellular signaling. 
Results
Effect of AGEs and statin on VSMC proliferation
In order to investigate whether statin affects RASMC 
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Figure 4. Effect of AGEs and statin on phosphorylation of MAPK in RASMCs treated with AGEs. Western blot for ERK and p38 in AGEs- or statin-treated 
RASMCs. The AGEs-treated one revealed increased activation of ERK (A) and p38 (B) and decreased activation with 1 μM of statin. Symbols - and + in-
dicate the absence and presence of AGEs or simvastatin, respectively. Data show a representative gel of ERK and p38 products and a bar graph of data 
quantitated as relative expression (a.u.) over respective control (mean ± SEM) (n = 5). *P ＜ 0.05 versus control, †P ＜ 0.05 versus AGEs-treated. 
AGEs, advanced glycation endproducts.
Figure 3. Effect of statin on activation of NFκB p65 in RASMCs treated 
with AGEs. Western blot for β-actin is shown as a protein loading control. 
Compared to cells treated with AGEs alone, cells treated with statin dem-
onstrated significant inhibition of NFκB p65 expression. Symbols - and + 
indicate the absence and presence of AGEs or simvastatin, respectively. 
Data show a representative gel of NFκB p65 products and a bar graph of 
data quantitated as relative expression (a.u.) over respective control 
(mean ± SEM) (n = 5). *P ＜ 0.05 versus control, †P ＜ 0.05 versus 
AGEs-treated. AGEs, advanced glycation endproducts.
proliferation upon AGEs treatment, RASMCs were 
treated with AGEs in the presence or absence of 
statin and cell proliferation assay was performed. 
As shown in Figure 1A, AGEs-induced increase in 
cell proliferation and augmentation of cell prolife-
ration induced by 50 μg/ml of AGEs were concen-
tration-dependent (7.2 ±2.4-fold increase compared 
to controls at 50 μg/ml of AGEs). The maximal 
response was obtained at 50 μg/ml of AGEs. Statin 
inhibited augmentation of cell proliferation induced 
by AGEs in a dose-dependent manner (Figure 1B). 
Effect of AGEs and statin on formation of intracellular 
ROS in RASMCs
As shown in Figure 2A, the degree of oxidative 
stress is increased with AGEs treatment dose-de-
pendently and the increase was significant at 50 
μg/ml of AGEs (1.5 ± 1.0-fold increase compared 
to controls at 50 μg/ml of AGEs). Statin inhibited 
augmentation of oxidative stress induced by 50 
μg/ml of AGEs (Figure 2B).
Effect of statin on activation of NFκB p65 in RASMCs 
To confirm the inhibitory effect of statin on expre-
ssion of NFκB, changes in NFκB p65 levels were 
estimated by immunoblot analysis. AGEs (50 μg/ml) 
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Figure 5. Effect of siRNA molecules targeted at RAGE on phosphor-
ylation of MAPK in RASMCs treated with AGEs. Western blot for ERK in 
AGEs-, siRNA-, or statin-treated RASMCs. For function-blocking experi-
ments, siRNA molecules targeted at RAGE mRNA was used. There was 
no difference in ERK activation between both and individual treatment 
with statin and siRNA for RAGE. Symbols - and + indicate the absence 
and presence of AGEs, simvastatin, or siRNA, respectively. Data show a 
representative gel of ERK products and a bar graph of data quantitated 
as relative expression (a.u.) over respective control (mean ± SEM) (n =
5). *P ＜ 0.05 versus control, †P ＜ 0.05 versus AGEs-treated. AGEs, 
advanced glycation endproducts; siRNA, small interfering RNA.
induced several-fold increase in NFκB p65 (2.1 ± 
1.3-fold increase compared to controls) expression 
but statin significantly inhibited AGEs-induced aug-
mentation of NFκB expression (Figure 3). 
Effect of AGEs and statin on phosphorylation of 
MAPK in RASMCs 
To confirm the inhibitory effect of statin on expre-
ssion of MAPK, changes in MAPK levels were 
estimated by immunoblot analysis. AGEs (50 μg/ml) 
induced several-fold increase in ERK and p38 (3.1 
± 1.2-fold and 2.9 ± 1.0-fold increase compared 
to controls) expression but statin significantly 
inhibited AGEs-induced augmentation of ERK and 
p38 expression (Figure 4). This suggests that 
statin significantly inhibits activation of MAPK 
increased with AGEs. 
Effect of statin and siRNA on activation of MAPK in 
RASMCs  
To determine whether AGEs are coupled to ERK 
activation via RAGE, siRNA for RAGE was pre-
treated. Fifty μg/ml of AGEs increased phosphory-
lation of ERK 1.7 ± 0.8-fold compared to controls 
and 10 μM of statin decreased phosphorylation of 
ERK. Additionally, AGEs-induced ERK activation 
was decreased to basal control level by RAGE 
inhibition. Furthermore, there was no difference in 
ERK activation between both and individual treat-
ment with statin and siRNA for RAGE. These 
results indicate that RAGE mediated ERK activa-
tion by AGEs and statin blocked the process 
induced by RAGE-AGE interaction (Figure 5).
Effect of statin on suppression of c-jun and COX-2 
mRNA expression in RASMCs
The inhibition of expression of c-jun and COX-2 at 
the mRNA level was demonstrated by RT-PCR. 
The treatment of RASMCs with AGEs resulted in 
increased expression levels of c-jun and COX-2, 
which were reduced by pretreatment with statin 
(Figure 6). The results indicated that statin has an 
inhibitory effect on expression levels of c-jun and 
COX-2. 
Impact of statin on neointimal hyperplasia and 
expression of COX-2 in carotid artery of diabetic rat
Compared to controls, neointimal formation in the 
carotid artery of diabetic model showed increased 
proliferation. However, diabetic model treated with 
statin showed more reduced neointimal formation 
than those not treated (Figure 7A-C and bar 
graph). COX-2 staining was more abundant in 
lesions of the carotid artery from AGEs-treated rats 
but markedly decreased after diabetic model was 
treated with statin (Figure 7D-F).
Discussion 
In the present study, we provide evidence of the 
critical involvement of statin in the process of 
AGEs-induced intracellular ROS formation of 
VSMCs. Furthermore, the present findings are the 
first, to our knowledge, to demonstrate a mechanism 
of inhibitory effect of statin on the process of 
developing diabetic vasculopathy in view of 
AGEs-induced intracellular oxidative stress and 
consequent cellular signaling. 
    Type 2 diabetes mellitus (DM) patients without a 
prior myocardial infarction (MI) have a similar risk 
for coronary artery-related events as non-diabetic 
individuals who have had a prior MI. Recent work 
has focused on the role of AGEs and RAGE in 
macro- and microvascular complications in DM, 
and there are several potential mechanisms by 
which AGEs may be involved in macrovascular 
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Figure 6. Effect of statin on suppression of protooncogene, c-jun, and COX-2 mRNA expression induced by AGEs. Expression levels of analysis by 
RT-PCR. Expression of c-jun (A) and COX-2 (B) revealed increase with AGEs and decrease with statin dose-dependently. Symbols - and + indicate the 
absence and presence of AGEs or simvastatin, respectively. Data show a representative gel of c-jun and COX-2 products and a bar graph of data quanti-
tated as ratio of protein to its respective GAPDH signal intensity (mean ± SEM) (n = 5). *P ＜ 0.05 versus control; †P ＜ 0.05 versus AGEs-treated. 
AGEs, advanced glycation endproducts.
disease (Kanauchi et al., 2001; Rojas and Morales, 
2004). Binding of AGEs to their receptor RAGE on 
cell surfaces including endothelial cells and VSMCs 
induces an intracellular oxidative stress response 
characterized by increased activation of transcrip-
tion factors such as NFκB (Baynes and Thorpe, 
1999). Oxidative stress of the vascular wall is a 
hallmark of atherosclerosis (Haendeler et al., 2004), 
and consequent activation of the NFκB and MAPK 
systems may be a possible mechanism of AGEs-in-
duced vasculopathy (Cuccurullo et al., 2006). More 
recently, the role of ROS as a signal molecule has 
gained increasing attention. The cytotoxicity of 
ROS may be associated with the effect on signal 
pathways such as NFκB to induce pathology. 
There are also studies demonstrating that treatment 
of monocytes with in vitro prepared AGEs or the 
specific RAGE ligand can significantly increase 
COX-2 mRNA and its proinflammatory products in 
THP-1 human monocytes (Shanmugam et al., 
2003). COX-2 and its proinflammatory products 
have been implicated in the pathogenesis of 
atherosclerosis, and it is also induced by oxidized 
lipids (Schonbeck et al., 1999; Hong et al., 2000; 
Burleigh et al., 2002; Pontsler et al., 2002). There 
are many studies demonstrating that interaction of 
RAGE and its ligand is closely correlated with cell 
migration, invasion, proliferation, survival and 
motility (Cipllone et al., 2003; Arumugam et al., 
2004; 2005) induced by intracellular signaling 
pathways, including GTPases, Cdc42, Rac, MAPK, 
ERK 1/2, p38, JNK and NFκB (Rauvala et al., 
2000; Taguchi et al., 2000). 
    Recent experimental studies suggested that the 
beneficial effects of statin in patients at risk for 
cardiovascular disease are not only a result of an 
improved lipid profile but also mediated by direct 
vasculoprotective actions (anti-inflammatory and 
endothelial cell protective actions) (Oda and 
Keane, 1999; Takemoto and Liao, 2001; Haendeler 
et al., 2004; Senokuchi et al., 2005). Moreover, in a 
recent study, RAGE suppression by simvastatin is 
emphasized to be largely dependent on the 
reduction of AGEs generation by myeloperoxidase. 
The antioxidant effects of statin are especially 
important in aspects of diabetic complications such 
as macro- or microvascular pathology but little is 
known about the pleiotrophic action of statin on 
AGEs. 
    ROS itself is known to be induced by the 
activation of NADPH oxidase from the reaction 
between AGE and RAGE, therefore, we investigated 
whether statin blocks VSMC proliferation through 
inhibition of ROS-induced proliferation and the 
inflammation pathway. This hypothesis was derived 
from the point that AGE-RAGE interaction may be 
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the upstream mechanism that increases formation 
of ROS and resultant VSMC proliferation. Therefore, 
we designed a schema showing the possible 
cascade of mechanism of diabetic vasculopathy 
induced with AGEs and the inhibitory action of 
statin in this process (Figure 8). 
    Our data showed increased cell proliferation and 
inflammatory reactions with AGEs treatment in 
dose-dependent manner and reduced cell prolife-
ration, inflammatory cellular signaling and protein 
expression of RASMC with statin. To clarify the 
inflammatory and proliferative actions, we used 
proteins of NFκB p65, p38, ERK, COX-2, and c-jun 
as important factors in inflammatory cascade. 
Cuccurullo et al. (2006) characterized the effect of 
simvastatin on the expression of RAGE and 
RAGE-dependent plaque-destabilizing genes such 
as COX-2 in human atherosclerotic plaques. They 
hypothesized that simvastatin might inhibit plaque 
RAGE expression by decreasing MPO-dependent 
AGE generation and in turn, contribute to plaque 
stabilization by inhibiting biosynthesis of 
PGE2-dependent metalloproteinase, responsible 
for plaque rupture (Cipllone et al., 2003). Our data 
did not show the difference of AGE or RAGE 
expression between controls and those treated 
with statin. This may be a limitation of our study, 
but our hypothesis that statin may block the 
process from RAGE-AGE interaction to ROS 
generation was supported by siRNA data.
    To determine whether statin suppresses cellular 
signaling induced by RAGE-AGE interaction, we 
examined the effect of siRNA molecules targeted 
at RAGE mRNA for function-blocking experiments. 
ERK activation was increased compared to 
controls with AGEs and decreased activation was 
Figure 7. H&E staining and immunohistochemistry for COX-2 of sections of carotid artery from 
controls and AGEs- and statin-treated rats. The statin-treated model (C) showed similar intimal 
thickness to controls (A) but more reduced neointimal hypertrophy than those not treated (B) 
(×100, H&E staining). COX-2 staining was more abundant in lesions from AGEs-treated model 
(E) than controls (D) or statin treated (F). Immunohistochemical analysis of the carotid artery 
stained (×200) with specific antibodies for COX-2.
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Figure 8. Schema of possible mechanism of inhibitory effect of statin on 
AGEs-induced vasculopathy. In the cascade of AGEs-induced ROS for-
mation and inflammatory and proliferative cellular signaling, statin may 
act as a blocker of the process from AGE-RAGE interaction to ROS 
generation.
examined with statin. In addition, AGEs-induced 
ERK activation was decreased to basal control 
level by RAGE inhibition. Furthermore, there was 
no difference in ERK activation between both 
individual treatment with statin and siRNA for 
RAGE. This indicates that RAGE mediated ERK 
activation by AGEs and statin blocked the process 
induced by RAGE-AGE interaction. 
    Recent experimental studies emphasize the 
antioxidative effects of statin and suggest that statin 
reduces ROS in endothelial cells by S-nitrosylation 
of thioredoxin (Takemoto and Liao, 2001; Haendeler 
et al., 2004). Recently, several reports have 
suggested that statin could act as an antioxidant in 
experimental atherosclerosis in rabbits (Giroux et 
al., 1993; Singh et al., 1997; Takemoto et al., 200; 
Wassmann et al., 2002), inhibiting oxidation of LDL 
by activated monocyte-derived macrophages. The 
ROS formation in our data increased with AGEs 
stimulation and reduced with statin treatment in 
dose-dependent manner as in other studies. 
    And in vivo study, many other articles revealed 
the anti-atherogenic effects of statin by using 
vascular injury model (Komukai et al., 1999; Chen 
et al., 2002) and have suggested that the inflam-
matory and proliferative responses are enhanced 
in diabetes and may explain the observed increa-
sed restenosis rate (Kornowski et al., 1997; Park et 
al., 2001), that was the same with this study.  
    In the present study, statin reduced AGE-RAGE 
interaction-induced increased intracellular oxidative 
stress (ROS) and ROS-induced cellular signaling 
in VSMCs. Consequently, it brought the suppre-
ssion of neointimal hypertrophy and expression of 
COX-2 in the carotid artery of diabetic rat model. 
However, it remains possible that statin also has 
many additional effects on diabetic vasculopathy 
and further studies will be necessary to fully 
understand the action of statin.
    We used a high dose of 20 mg/kg in rats but the 
dose in humans is lower, so the limitation can be 
that we did not suggest the clinical dose in 
humans. Because the effect of various chemical 
structures of statins on ROS formation can be 
different and we used only one type of statin, it 
may be another limitation of this study.    
    The antioxidant effects of statin are especially 
important in aspects of diabetic complications such 
as macro- or microvascular pathology. This study 
demonstrated the possible mechanism of action of 
statin on the antiproliferative effects of VSMCs of 
diabetic model. Conclusively, statin is expected to 
play a key role in the treatment of AGEs-induced 
diabetic vasculopathy.
Methods
Experimental materials and animals
The HMG CoA reductase inhibitor simvastatin was a 
generous gift from MRL (Merck & Co., Inc., Rahway, NJ). 
    Six- to eight-week-old male Sprague-Dawley rats (200 g 
initial weight) were given standard chow and water. They 
were injected with streptozocin (STZ, 80 mg/kg) via 
intraperitoneal route and hyperglycemia was confirmed by 
blood glucose meter (Accu-Chek Advantage, Boehringer 
Mannheim, Mannheim, Germany) within 1 wk post-STZ. 
Diabetic models were confirmed by blood glucose levels 
over 250 mg/dl. Rats treated with STZ that did not 
demonstrate significant elevation of blood glucose (＜250 
mg/dl) were excluded from the study. Animals were 
handled in compliance with the Guiding Principles in the 
Care and Use of Animals. Twenty mg/kg of statin was 
mixed with pulverized standard chow and 5 rats were 
treated for 8 wks from the 16th wk. After 8 wks, carotid 
artery balloon injury was performed and after 4 wk of more 
treatment, rats were sacrificed for analysis. The investiga-
tion conforms with the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes 
of Health (NIH Publication No. 85-23, revised 1996).
Isolation of rat aortic smooth muscle cells (RASMC) 
and cell culture
Rat aortic smooth muscle cells (RASMCs) were isolated as 
previously described (Takemoto and Liao, 2001). The 
thoracic aortas from 6- to 8-wk-old rats were removed and 
transferred in serum-free DMEM (Invitrogen Co., Carlsbad, 
CA) containing 100 units/ml of penicillin and 100 μg/ml of 
streptomycin. The aortas were freed from connective 
tissue, transferred to a Petri dish containing 5 ml of an 
enzyme dissociation mixture containing DMEM with 1 
mg/ml of collagenase type I (Sigma, St. Louis, MO) and 0.5 
μg/ml of elastase (USB Bioscience, Cleveland, OH), and 
incubated for 30 min at 37oC. The aorta was then 
transferred in DMEM and the adventitias were stripped off 
with forceps under a binocular microscope. The aortas 
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were transferred to a plastic tube containing 5 ml of the 
enzyme dissociation mixture and incubated for 2 h at 37oC. 
The suspension was centrifuged (1,500 rpm for 10 min) 
and the pellet was resuspended in DMEM with 10% FBS. 
Rat aortic VSMCs were cultured in DMEM supplement with 
10% FBS, 100 IU/ml of penicillin, and 100 μg/ml of 
streptomycin in 75-cm2 flasks at 37oC in a humidified 
atmosphere of 95% air and 5% CO2 (Forma Scientific, Inc., 
Marjetta, OH).
RASMC proliferation assay
Cellular proliferation was measured by PreMix WST-1 Cell 
Proliferation Assay System (TAKARA Biomedicals, Shiga, 
Japan). This system enables measurement of cell proli-
feration with colorimetric assay based on the cleavage of 
slightly red tetrazolium salt (WST-1) by mitochondrial 
succinate-tetrazolium reductase in viable cells. As the 
increase in enzyme activity leads to an increase of 
production of formazan dye, the quantity of formazan dye 
is directly related to the number of metabolically active 
cells in the medium. Cells (5-7 × 103) were seeded into 
wells of a 96-well culture plate and incubated with AGEs 
for the times indicated. WST-1 cell proliferation reagent 
was added directly to the supernatant (10 μl/100 μl growth 
medium) and incubated at 37oC for 3 h. The absorbency of 
the solubilized dark red formazan product was then 
determined at 450 nm.
AGEs and statin treatment
Cultured RASMCs were co-incubated with prepared 
BSA-AGEs solution (Sigma, St. Louis, MO) at each conce-
ntration of 1, 10, 50, 100 and 1,000 μg/ml for 2 h at 37oC. 
Simvastatin (Merck & Co., Inc., Rahway, NJ) was pre-
treated for inhibition experiment. AGEs-stimulated RASMCs 
were incubated with 0.1, 1, 5, 10, 20, 50 and 100 μM of 
activated statin for 1 h before AGEs stimulation. Statin was 
activated via alkaline hydrolysis as previously described 
(Jones et al., 2001). 
Measurement of intracellular ROS generation
RASMCs were labeled with 2',7'-dichlorodihydrofluorescein 
diacetate (H2DCFDA; Molecular Probe, CA) as previously 
described (Haendeler et al., 2004). The probe H2DCFDA 
(5 μM) entered the cell and the acetate group on 
H2DCFDA was cleaved by cellular esterases, trapping the 
non-fluorescent 2',7'-dichlorofluorescin (DCF) inside.  
    Subsequent oxidation by ROS yields the fluorescent 
product DCF. The dye, when exposed to an excitation 
wavelength of 480 nm, emits light at 535 nm only when it 
has been oxidized. Labeled RASMCs were examined 
using a luminescence spectrophotometer for oxidized dye. 
The quiescent cells were treated with AGEs for 3 h before 
labeling with H2DCFDA..
SDS-PAGE and Western blot analysis for NFκB p65, 
p-ERK, and p-P38
VSMCs were solubilized in a lysis buffer (20 mM Tris, pH 
7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% 
Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycero-
phosphate, 1 mM Na3VO4, 1 mM PMSF, 1 μg/ml aprotinin, 
and 1 μg/ml leupeptin) and centrifuged at 12,000 g for 20 
min at 4oC. The protein concentrations of the supernatants 
were determined using a Bradford protein assay kit 
(Bio-Rad, Hercules, CA). Cell lysates containing equal 
amounts of protein were subjected to SDS-PAGE, and the 
proteins were transferred to PVDF membrane (Millipore, 
Bedford, MA). After blocking in 10 mM of Tris-HCl buffer 
(pH 8.0) containing 150 mM of sodium chloride, 0.1% 
Tween 20, and 5% (w/v) nonfat dry milk, the membrane 
was treated with NFκB p65, p-ERK, and p-P38 primary 
antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, 
CA), followed by incubation with appropriate HRP-conju-
gated secondary antibodies. The antigen-antibody bands 
were detected using an enhanced chemiluminescence 
reagent kit (Amersham Bioscience, Uppsala, Sweden) and 
quantified by densitometry.
RNA interference for RAGE mRNA
For function-blocking experiments, siRNA molecules tar-
geted at receptor for AGE (RAGE) mRNA was used. A 
21-nt sequence for siRNA was derived from rat RAGE 
(GenBank accession No. GI: 81722) and obtained from 
Ambion, Inc. (TX): siRNA against RAGE (sense, 5'-GCUAG-
AAUGGAAACUGAACtt-3'; antisense, 5'-GUUCAGUUUC-
CAUUCUAGCtt-3'). RSMCs were transfected with si-RAGE 
duplexes by using siPORT NeoFX (Ambion). 
    Briefly, RNA duplex (10 nM of final concentration) was 
incubated in serum-free DMEM containing 15 μl of siPORT 
NeoFX for 10 min. The complex was added to the empty 
60 mm culture plate and then overlay SMC suspension (1 
× 105 cells per plate) onto the culture plate wells con-
taining transfection complexes. The transfected cells were 
incubated in normal cell culture conditions until ready for 
assay. 
RT-PCR analysis for COX-2 and c-jun
Total RNA was prepared by the UltraspectTM-II RNA system 
(Biotecx Laboratories, Inc., TX), and single-stranded cDNA 
was then synthesized from isolated total RNA by avian 
myeloblastosis virus (AMV) reverse transcriptase. A 20 μl 
reverse transcription reaction mixture containing 1 μg of 
total RNA, 1× reverse transcription buffer (10 mM Tris-HCl, 
pH 9.0, 50 mM KCl, 0.1% Triton X-100), 1 mM deoxynu-
cleoside triphosphates (dNTPs) 0.5 unit of RNase inhibitor, 
0.5 μg of oligo (dT)15, and 15 units of AMV reverse 
transcriptase was incubated at 42oC for 15 min, heated to 
99oC for 5 min, and then incubated at 0-5oC for 5 min. 
PCRs were performed for 35 cycles with 3' and 5' primers 
based on the sequences of various genes. Primers were 
as follows: c-jun: 5'-AACGACCTTCTACGACGATG-3', 5'- 
GCAGCGTATTCTGGCTATGC-3' (364 bp); COX-2: 5'-TC-
CAATCGCTGTACAAGCAG-3', 5'-TCCCCAAAGATAGCA-
TCTGC-3' (230 bp). GAPDH (primers 5'-ACCACAGTCCA-
TGCCATCAC-3' and 5'-TCCACCACCCTGTTGCTGTA-3' 
(450 bp) was used as the internal standard. The signal 
intensity of the amplification product was normalized to its 
respective GAPDH signal intensity.
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Induction of neointimal formation after balloon 
denudation in diabetic rat carotid artery 
Balloon denudation of the common carotid artery endo-
thelium was evoked in 16-wk-old diabetic Sprague-Dawley 
rats (400 g). Under isoflurane (Abbott Laboratories, St. 
Laurent, QC) anesthesia, a neck midline incision was 
made and after exposure of the left carotid artery, a 2F 
Fogarty balloon catheter (Edwards Lifesciences, Missi-
ssauga, ON) was inserted into the external carotid branch 
to the aortic arch and insufflated (with about 0.2 ml of 
saline) to produce slight resistance and withdrawn 3 times. 
After 4 wk, they were compared to sham-operated controls 
in which the same procedure was performed, except 
balloon insertion. Animal housing and experimentation in 
accordance with Animal Care and NIH guidelines were 
approved by the local animal care committee. 
Perfusion of vessels, hematoxylin and eosin 
staining, and immunochemistry for COX-2 in rat 
carotid artery 
The hearts were perfused with Krebs-Ringer Bicarbonate 
Buffer (KRBB: 120 mM NaCl, 25 mM NaHCO3, 5 mM KCl, 
1.2 mM KH2PO4, 1.2 mM MgSO4, 2.5 mM CaCl2, and 20 
mM MOPS) for 10 min to wash out the blood, and then 
fixed with 10% formalin. 
    The carotid arteries were sliced transversely. Within 24 h 
after fixation, each of the sections was embedded in 
paraffin. Serial 2 μm artery sections were cut with micro-
tome and mounted on siliconized slides. Paraffin sections 
were stained with hematoxylin and eosin (H&E) and eva-
luated with light microscopy to assess the histological 
effects. Normal and neointimal areas were measured using 
NIH images. 
    Serial sections were prepared and immunohistochemistry 
to detect COX-2 was performed using polyclonal mono-
specific antibodies to COX-2 (Abcam plc., Cambridge, UK).
Statistical analysis
Data are presented as mean ± SEM. Differences between 
2 experimental groups were examined by Student's t test. 
One-way ANOVA followed by post hoc paired comparisons 
for comparison of multiple groups and ANOVA for repeated 
measures were used as appropriate (SPSS software). A 
value of P ＜ 0.05 was considered significant.
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